EAST RUTHERFORD, NJ, Sept. 1, 2022 /PRNewswire/ — Cambrex as we speak introduced the completion of the primary section of its $30 million funding in its small molecule lively pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina. The newly constructed area provides analytical and chemical growth laboratories totaling 30,000 sq. toes and offers future workspace for 85 analytical and chemical growth scientists. These laboratories will assist the event of APIs to be manufactured in the ability’s present medical manufacturing space, in addition to the longer term expanded medical manufacturing and industrial manufacturing suites.
“With the growing number of therapies in clinical development and trend toward more targeted therapeutics, including orphan drugs, this expansion is preparing Cambrex to support the growing demand for small-scale API manufacturing,” mentioned Tom Loewald, CEO, Cambrex. “Our expansion goes beyond providing capacity – it provides state-of-the-art technology and laboratory equipment, an energy efficient infrastructure, and an ideal space for our scientific experts to work side-by-side with our clients.”
Phase 2 of the undertaking is ongoing and can roughly double the ability’s manufacturing capability with the addition of medical and industrial manufacturing suites with reactors as much as 2,000 liters. The new industrial space will present a perfect scale for the manufacturing of orphan medicine and area of interest therapies, whereas bigger quantity merchandise developed on the facility will be manufactured commercially at one of Cambrex’s bigger scale services in Iowa and Sweden. This growth follows Cambrex’s 2021 funding in the Cambrex High Point steady circulate R&D middle of excellence, together with expanded capabilities for steady circulate course of growth, manufacturing, and scale up.
Cambrex continues to develop its capabilities and capability throughout its North American and European community to fulfill the rising demand for outsourced product growth and manufacturing companies.
About Cambrex
Cambrex is a number one world contract growth and manufacturing group (CDMO) that gives drug substance, drug product, and analytical companies throughout your complete drug lifecycle. With over 40 years of expertise and a rising group of over 2,300 consultants servicing world shoppers from North America and Europe, Cambrex is a trusted accomplice in branded and generic markets for API and completed dosage kind growth and manufacturing.
Cambrex affords a variety of specialised drug substance applied sciences and capabilities, together with biocatalysis, steady circulate, managed substances, solid-state science, materials characterization, stability storage, and extremely potent APIs. In addition, Cambrex can assist standard dosage types, together with oral solids, semi-solids, and liquids, and has the experience to fabricate specialty dosage types reminiscent of modified-release, fixed-dose mixture, pediatric, bi-layer tablets, stick packs, topicals, managed substances, sterile, and non-sterile ointments.
Contact:
Jennifer Therrien
[email protected]
Photo – https://mma.prnewswire.com/media/1889203/Cambrex_1.jpg
Photo – https://mma.prnewswire.com/media/1889204/Cambrex_2.jpg
Logo – https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg
